Instrument Inactif

Communiqués InspireMD Inc Nyse

Actions

US45779A3095

Cours en clôture Nyse Autres places de cotation
- ^USD	-

14/05	Transcript : InspireMD, Inc., Q1 2024 Earnings Call, May 14, 2024
13/05	InspireMD, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption Clinical Trial of CGuard at LINC 2024	29/05	AQ
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024	28/05	AQ
InspireMD : Reports First Quarter 2024 Financial Results and Provides Business Update	14/05	PU
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th	07/05	AQ
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference	03/04	AQ
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024	26/03	AQ
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	06/03	AQ
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th	28/02	AQ
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System	12/02	AQ
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework	31/01	AQ
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America	03/01	AQ
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System	20/12	AQ
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions	27/11	AQ
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update	06/11	AQ
InspireMD to Participate in Upcoming November Investor Conferences	02/11	AQ
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23	01/11	AQ
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th - InspireMD	31/10/23	AQ
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th	30/10/23	AQ
InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients	12/10/23	AQ
InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives	03/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués InspireMD Inc Nyse

Actions

US45779A3095

Communiqués

Filtres